Zacks Research Has Negative Estimate for EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at Zacks Research lowered their Q1 2025 EPS estimates for shares of Edwards Lifesciences in a report released on Thursday, November 14th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $0.59 per share for the quarter, down from their prior forecast of $0.69. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.62 EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.64 EPS, Q1 2026 earnings at $0.67 EPS, Q2 2026 earnings at $0.70 EPS and Q3 2026 earnings at $0.71 EPS.

EW has been the topic of a number of other reports. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Evercore ISI lowered their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Finally, Wells Fargo & Company dropped their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $70.20 on Monday. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The company’s 50 day moving average price is $67.59 and its two-hundred day moving average price is $75.91. The stock has a market cap of $41.40 billion, a P/E ratio of 10.13, a P/E/G ratio of 3.81 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the firm earned $0.59 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter worth $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences during the second quarter worth about $29,000. Webster Bank N. A. bought a new stake in Edwards Lifesciences during the second quarter worth about $39,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $30,000. Finally, Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 326 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,000 shares of company stock worth $2,657,000. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.